COVID-19 vaccine: Study on long-term outcomes of myocarditis and pericarditis following vaccination

This study was about the long-term health outcomes of myocarditis and pericarditis symptoms following vaccination with Comirnaty (Pfizer/BioNTech COVID-19 vaccine) in 2022. The purpose of this study was to survey people about their experiences with myocarditis and/or pericarditis, including impacts on their current health, mental health, physical functioning, and daily activities. The study was not designed to confirm whether the cases of myocarditis and/or pericarditis were related to or caused by the vaccine.

About myocarditis and pericarditis

The study team would like to express our gratitude to the participants of this study who have shared their experiences of myocarditis and/or pericarditis and their journeys. We would also like to acknowledge and thank the healthcare professionals for their participation in the survey.

The publication of the survey results, including the participant summary and full report, can be found below.

Report

Long-term outcomes of myocarditis and pericarditis following vaccination with Comirnaty (Pfizer/BioNTech COVID-19 vaccine): A survey of adolescents, adults, and their healthcare professionals in Aotearoa New Zealand (PDF 996KB)

Long-term outcomes of myocarditis and pericarditis following vaccination with Comirnaty (Pfizer/BioNTech COVID-19 vaccine): A survey of adolescents, adults, and their healthcare professionals in Aotearoa New Zealand (DOCX 781KB)

Participant summary

Long-term outcomes of myocarditis and pericarditis following vaccination with Comirnaty (Pfizer/BioNTech COVID-19 vaccine): Participant summary (PDF 339KB)

Long-term outcomes of myocarditis and pericarditis following vaccination with Comirnaty (Pfizer/BioNTech COVID-19 vaccine): Participant summary (DOCX 987KB)

Data files

Adult consumer survey dictionary and responses (XLS 55KB)

Child consumer survey dictionary (XLS 42KB)

Health care providers survey dictionary and responses (XLS 44KB)

Minutes

Minutes - MyoPeri-ROC (PDF 1.1MB)

We encourage individuals to report any reactions to a vaccine to the Centre for Adverse Reactions Monitoring (CARM).

Submit a report online to CARM

You do not need to be a health professional to submit a report and you do not need to be certain that the reaction was caused by the vaccine. Reporting to CARM does not initiate any personal medical advice or treatment.

Information given to the interviewer during the study is protected by the Privacy Act 2020. Information was aggregated for analysis and will remain confidential.

In the future, health researchers may want to contact participants about follow-up research on health, or health services, relating to myocarditis and pericarditis. We will only contact participants if they consented for this at the end of the interview.

For more information about the study, email C19myostudy@tewhatuora.govt.nz.

Trial registration – The Australian New Zealand Clinical Trials Registry